Funding
← Back to your selection

Leaps by Bayer

Activity from announced rounds

Activity in this selectionUnited States · Oct 23, 2026 · Jan 1, 2026

Leaps by Bayer is the venture investment organization whose official news identifies Robigo and Sabanto.

Recorded funding activity

Robigo develops microbial crop protection. Sabanto retrofits agricultural equipment for autonomous operation, while Celea develops respiratory medicines. These company relationships belong to the Leaps organization separately from the Bayer parent.

Sources
Rounds participated in
5
Confirmed lead rounds
1
3 roles undisclosed
New companies
5
First participation on record · 0 follow-on
Funding in participating rounds
$440M
3 disclosed · full round size, not this investor’s share

By stage

Series B3
Growth1
Series A1

By primary sector

Biotech3
Agritech2

By country

United States5

Rounds

5 in this selection
Soufflé Therapeutics

Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.

$135MSeries B
Participant
Robigo

Robigo engineers biological crop-protection solutions that use targeted microbes to control plant pathogens while preserving beneficial organisms.

UndisclosedSeries A
Lead
Sabanto

Sabanto develops autonomous retrofit technology for agricultural equipment.

UndisclosedSeries B
Role not disclosed
SonoThera

Develops ultrasound-mediated nonviral genetic medicines

$125MSeries B
Role not disclosed